Upstream Bio, Inc. operates as a clinical-stage biotechnology company. The Company focuses on developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. Upstream Bio serves customers in the United States.

Quarterly Report (Form 10-Q | Period ending 2024-09-30)

Current Report (Form 8-K | Period ending 2024-11-07)

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Upstream Bio (UPB US)

Quarterly Report (Form 10-Q | Period ending 2024-09-30)

Current Report (Form 8-K | Period ending 2024-11-07)

Current Report (Form 8-K | Period ending 2024-10-10)

S-8 | Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

424B4 | Prospectus

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)